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ABSTRACT 
PREVALENCE OF NONALCOHOLIC FATTY LIVER 
DISEASE AND METABOLIC SYNDROME IN PSORIASIS IN 
A TERTIARY HEALTH CENTER 
Abarna Devi S. R Penchalaiah. K. Narayanaswamy. 
INTRODUCTION: Psoriasis vulgaris is a common dermatological 
condition, worldwide, with a higher prevalence of 0.8-5.6% India. 
Psoriasis is not just skin deep, and psoriasis patients suffer with many 
systemic illness directly or indirectly.  
AIMS AND OBJECTIVES: To study the prevalence of nonalcoholic 
fatty liver disease and metabolic syndrome in psoriasis in south Indian 
population and to correlate the severity of psoriasis with the prevalence 
of NAFLD . 
MATERIALS AND METHODS: Ours is a cross sectional study 6 
months, with 165 psoriasis patients. Psoriasis patients on hepatotoxic 
drugs, significant alcohol use are excluded from the study. After 
clinical history and examination all the patients are subjected to battery 
of investigations including ultrasonography. 
1. Post Graduate, Institute of Internal Medicine, RGGGH, Chennai. 
2. Professor of Medicine, Institute of Internal Medicine, RGGGH, Chennai. 
3. Head of Department, Department of Hepatology, RGGGH, Chennai. 
RESULTS: The prevalence of NAFLD and metabolic syndrome 
among psoriasis in our study is 75(45.5%) and 27(16%) respectively. 
All other components of metabolic syndrome are also increased in our 
study. There is no association of NAFLD with severity of psoriasis. 
Patients with psoriasis and metabolic syndrome had significant 
dyslipidemia. 
CONCLUSION: There is a significant association between psoriasis 
and metabolic syndrome and NAFLD. Psoriasis is independently 
associated with NAFLD. 
KEY WORDS: Psoriasis, NAFLD, metabolic syndrome. 
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INTRODUCTION 
Psoriasis vulgaris as the name implies is a common dermatological 
condition, worldwide with a prevalence of 1.5%-3% (1).A study in India 
quotes a higher prevalence of 0.8-5.6% ,(2) as environmental factors play a 
role with countries at greater latitudes from equator have a higher prevalence.   
It is now recognized that psoriasis is not just skin deep, and psoriasis 
patients suffer with many systemic illness directly or indirectly .Various 
studies across the world have demonstrated a chronic systemic inflammatory 
state of psoriasis which predisposes these patients to a higher relative risk of 
several comorbidities affecting almost all the system of the body .it is well 
known that psoriasis patients have a higher prevalence of coronary artery 
disease(3) and suffer early mortality. 
Onesuch comorbidity which has gained importance is metabolic 
syndromeand its sequel which is alarming. 
While treating a psoriasis patient, the treating Physician or 
Dermatologist should keep in mind, regarding various comorbidities 
associated with psoriasis for the following reasons: 
(I)To create an awareness among the psoriasis patients about the 
various comorbidities  
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(ii) To educate these patients on various primary and secondary 
prevention modalities of non-communicable illness which are relatively more 
prevalent among psoriasis patients. 
(iii) Physicians should be aware of the guidelines recommended for 
monitoring psoriasis patient, for early detection of comorbidities and 
treatment. 
(iv) Physician’s should be aware of the various treatment modalities of 
psoriasis, to keep a check on drug interactions, while treating systemic 
illness. 
This study is designed to know the magnitude of metabolic syndrome 
among psoriasis patients in our region . 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVES 
To study the prevalence of nonalcoholic fatty liver disease in psoriasis 
in south Indian population. 
1. To study the prevalence of metabolic syndrome in psoriasis in south 
Indian population  
2. To correlate the severity of psoriasis with the prevalence of NAFLD 
3. To find the association of nonalcoholic fatty liver disease and 
metabolic syndrome with age, severity and type of psoriasis. 
 
SECONDARY OBJECTIVES 
4. To find the association of nonalcoholic fatty liver disease and 
metabolic syndrome with age, severity and type of psoriasis. 
5. To establish psoriasis as a systemic disease and the need for screening 
of psoriasis patients for NAFLD and metabolic syndrome. 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
PSORIASIS VULGARIS 
Psoriasis is a multisystemdisease, predominantly affecting skin, nails, 
and joints. The prevalence of psoriasis is around 1.5 -3% worldwide and it 
affects both the sex equally, with bimodal distribution. There are two types of 
psoriasis, type I which is familial, occurs in young age group, with preceding 
streptococcal infection and type II occurs without any preceding infectious 
trigger(1),(13). 
 
HISTORICAL ASPECTS 
“Psora” in Greek means itch .Its first description dates back to biblical 
times, nearly 3000 years back, as it is documented in Old Testament by 
Moses .The term psoriasis was first used by Galen.(4) 
Psoriasis is a multifactorial,multisystem disease, resulting from 
interplay of genetic and environmental factors, causing dysregulation of 
innate and adaptive immune system. 
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PATHOGENESIS 
 
Psoriasis is chronic immune mediated inflammatory state resulting in 
state of hyper proliferation, predominately mediated by T helper cells. An 
early overt response of innate immune system to an antigenic trigger is 
responsible for the immune dysregulation in psoriasis. The recent concept is 
that psoriasis is mediated by Th17 cells. Stimulation of the antigen presenting 
cells in epidermis by cytokines like TNF-α, IL-6, IL-1β IFN-α, IFN-γ, due to 
an unknown antigen results in antigen presentation and release of IL-12 and 
IL-23 by dendritic cells.(5) 
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IL-23 is the key cytokine which results in differentiation of T cells to 
Th17 cells, which in turn release cytokines IL-17 and IL-22 leading to 
keratinocyte proliferation, production of antimicrobial peptides, 
proinflammatory cytokines and chemokine(6). 
Epidermal proliferation due to keratinocytes mainly occurs in basal and 
suprabasal layer, predominantly due to TGF alpha cytokine. 
 
ANGIOGENESIS 
Psoriasis is characterized by increased angiogenesis(1). Psoriatic lesions 
overexpress VEGF which is responsible for the angiogenic activity producing 
dilated, tall tortuous dermal capillaries. It is also considered responsible for 
systemic capillary leak in psoriatic patients which manifest as proteinuria, the 
level of which correlates with serum VEGF. There is up regulation of 
leukocyte homing molecules such as E-selectin, and ICAM expression on the 
surface of dermal capillaries due to inflammatory mediators like histamine, 
neuropeptides, IL-1, TNF alpha, the mechanism behind accumulation of skin 
homing T- lymphocytes in lesion.  
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GENETICS OF PSORIASIS  
Nine chromosomal loci PSORS1-PSORS 9(6) are identified,that are 
linked to psoriasis.PSORS1 is the major genetic determinant, responsible for 
nearly 30-50% of familial psoriasis. PSORS 8 gene overlaps with Crohn’s 
disease loci in chromosome 16q,which explains increased occurrence of 
Crohn’s in psoriasis. 
 
ENVIRONMENTAL FACTOR 
Several factors could trigger or exacerbate psoriasis like infections 
with staphylococcus aureus, candida species, malassezia furfur, streptococcus 
species,as well as smoking, sunlight, trauma are known to exacerbate 
psoriasis. 
 
DRUGS 
Lithium, antimalarial, ACE inhibitors,NSAID’S,beta blockers, 
clonidine, terfenadine, gemfibrosil, trazadone, potassium iodide, digoxin, 
amiodarone, penicillin, withdrawal of systemic steroids are known to 
exacerbate psoriasis.(8) 
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Other factors which may precipitate or exacerbate psoriasis include, 
hypocalcaemia, dialysis, alcohol intake, stress, HIV may exacerbate psoriasis 
 
CLINICAL FEATURES OF PSORIASIS 
The disease is characterized by recurrent exacerbations and remissions, 
of itchywell-defined erythematous, thickened, silvery white scaly papules and 
plaques predominantly affecting the extensor aspect of the body, involving 
minimal to entire body surface area involvement.  
 
Pustular psoriasis is characterized by the presence of macroscopic 
pustules and guttate psoriasis is identified by the presence of numerous tiny 
widespread erythematous scaly papules and plaques. Nails may be involved 
in 10-80% (9)of psoriasis patients affecting both nail bed and nail matrix and 
is characterized by subungual hyperkeratosis, splinter hemorrhages, oil drop 
sign, onycholysis. Psoriatic arthritis affects 10-30% of psoriasis patients. 
 
DIAGNOSIS 
 Psoriasis is mainly clinical and histopathology of the skin lesion is 
confirmatory. Psoriatic lesion may exhibit Auspitz sign(10),which is removal 
of thinned epidermis by scrapping, reveals multiple vascular bleeding points. 
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HISTOPATHOLOGY  
Psoriatic lesion reveals parakeratosis, orthokeratosis, munromicro 
abscess, thinning of granular layer, elongation and thinning of rete ridges, 
suprapapillarythinning of epidermis.(11) 
 
MORPHOLOGICAL TYPES OF PSORIASIS 
1. Chronic plaque psoriasis 
2. Pustular psoriasis(12) 
3. Erythrodermic psoriasis 
4.Guttate psoriasis 
 5. Psoriatic arthritis  
6. Mucous membrane psoriasis 
7. Rupioid , Elephantine and Ostraceous psoriasis.  
8. Follicular psoriasis 
9. Psoriasis unguis/nail psoriasis 
11. Unstable psoriasis 
12. Linear and Zonal forms(14) 
13. Sebopsoriasis 
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SEVERITY ASSESSMENT SCORES FOR PSORIASIS  
1) Psoriasis area and severity index (PASI) 
2) Dermatologylife quality index (DLQI) 
3) Body surface area (BSA) 
4) Visual analogue scale (VAS) 
5) Short form -36 
 
CALCULATION OF PSORIASIS AREA AND SEVERITY 
INDEX (PASI) : 
PASI score ranges from 0 to 72.it is the most widely used objected 
method to assess the disease severity and response to treatment 
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PSORIASIS –A SYSTEMIC ILLNESS 
Various studies across the world have proved that psoriasis is 
associated with many other systemic conditions. Multiple organ involvement 
is known to occur in psoriasis. Hence it is proved beyond doubt that psoriasis 
is a systemic illness(15). The comorbidities of psoriasis may be described 
based on the system affected. 
 
MUSCULOSKELETAL SYSTEM 
Psoriatic arthritis, osteoporosis, gout, chronic recurrent multifocal 
osteomyelitis can occur with pustular psoriasis, SAPHO syndrome(16) 
 
PSORIATIC ARTHRITIS: 
It is a chronic inflammatory arthropathy involving peripheral joints, 
spine, and entheses.It manifests as pain, swelling, tenderness of joints, 
tendon, and ligaments.It is considered as seronegative arthritis, in the sense it 
is negative for both rheumatoid factor and anti CCP(18). It may 
precede,accompany or follow psoriatic skin lesion. PsA may progress to 
erosive arthritis with joint destruction .the prevalence of PsA is more in 
severe psoriasis and prevalence of nail psoriasis is more in patients with PsA 
.An association with HLA B 27 is well known with PsA.(17) 
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MOLL AND WRIGHT CLASSIFICATION OF PSORIATIC 
ARTHRITIS: 
 
 
 
 
 
 
15 
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Differentiating Psoriatic Arthritis from Rheumatoid Arthritis 
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DIFFERENTIATING PSORIASIS FROM 
SPONDYLOARTHROPATHIES 
 
GASTROINTESTINAL SYSTEM: (19) 
Crohnsdisease, ulcerative colitis, celiac disease, gastro esophageal 
reflux disease is more prevalent among psoriasis patients. 
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PSORIASIS AND LIVER 
Psoriasis patents have higher relative risk of developing nonalcoholic 
fatty liver disease (NAFLD) and viral hepatitis .psoriasis patients suffer from 
drug induced hepatotoxicity due to methotrexate, acitretin, etc.(20) 
The prevalence of NAFLD among psoriasis is around 48-59%. 
Correlation between NAFLD and severity of psoriasis is not well established. 
Gisondi et al(21) study quotes that NAFLD was associated with the 
severity of psoriasis. Whereas Miele et al study showed NAFLD to be 
unrelated to psoriasis severity.Other finding from the same study is that 
psoriatic patients with NAFLD were more likely to have psoriatic arthritis. 
 
RENAL SYSTEM 
Case reports of acute tubular necrosis, poststreptoccocal 
glomerulonephritis have been described following pustular and guttate 
psoriasis respectively. Renal failure due to amyloidosis may be a sequel to 
arthropathic, pustular and severe non pustular psoriasis.(22) 
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RESPIRATORY SYSTEM 
Chronic obstructive pulmonary disease(COPD) is more common in 
psoriasis. Apical pulmonary fibrosis is reported to occur in association with 
psoriatic arthritis.(23) 
 
OCULAR SYSTEM 
Uveitis can occur in pustular psoriasis and psoriatic arthritis. Other 
ocular complications includes keratitis, blepharitis, conjunctivitis, 
symbhlepharon, xerosis. 
 
MALIGNANCY 
Psoriatic patients are at increases risk of developing non melanoma 
skin cancer and lymph proliferative malignancy probably due to 
immunotherapeutic agents and phototherapy. 
 
Lip, oral, pharyngeal, peritoneum carcinoma  are also more common 
among psoriasis. 
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CENTRAL NERVOUS SYSTEM 
Psoriasis is a pre atherosclerotic state,cerebrovascular accident are 
more common among psoriasis patients. It is one of the causes for mortality 
in psoriasis patients. 
Psoriasis more commonly occurs in families with multiple sclerosis. 
 
PSYCHOSOCIAL ASPECTS OF PSORIASIS 
Depression in psoriasis may be as high as 60%.They may also suffer 
from low self-esteem, sexual dysfunction,anxiety and sleep disorder 
Smoking and alcohol consumption is more common among psoriasis 
patients compared to the general population. 
 
CADIOVASCULAR SYSTEM 
Epidemiological studies have found an association between psoriasis 
and cardiovascular risk factors such as obesity, hypertension, dyslipidemia, 
diabetes mellitus, and the so called “Metabolic syndrome” the deadly quartet 
with psoriasis. Psoriasis is considered a state of preatherosclerolsis and hence 
is an independent risk factor for myocardial infarction conferring early 
mortality among psoriasis patients. (30) 
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Presence of hyperuricemia, phototherapy one of the treatment 
modalities of psoriasis contributes to atherosclerosis risk among psoriasis. 
Early use of methotrexate for psoriasis significantly reduced the 
atherosclerosis risk among psoriasis. (28) 
 
PSORIASIS AND METABOLIC SYNDROME 
Concept of psoriatic march: 
Chronic systemic inflammation causes a state of insulin resistance, 
which triggers endothelial cell dysfunction, which leads to atherosclerosis, 
resulting in CVD, CAD (29) 
Continuous effective systemic therapy may stop the psoriatic march. 
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PSORIATIC MARCH 
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OBESITY 
A study from UK has shown that psoriasis patients are 1.18 times 
higher risk of developing obesity.A study in Israel comparing obesity in 
psoriasis patients and control showed a significant p value .In this study 
obesity was present in 8.4% and 3.6% of psoriasis patients and controls 
respectively. 
Obesity produces a state of a chronic inflammatory state as the immune 
cells like macrophages infiltrates the adipose tissue, stimulates the production 
of adipokines.Adipokines are the key cytokines in pathogenesis of 
adipokines.  
Adipokines are the cytokines produced by adipose tissue, the largest 
endocrine organ.It is shown in studies that adipokines may be used as a 
biomarker for assessing the occurrence of comorbidities, severity of psoriasis. 
Various studies across the world have demonstrated that psoriatic patients are 
at risk of increase in BMI. It is stated that obesity predisposes to psoriasis and 
vice versa. A study conducted in China cites co-occurrence of obesity and 
HLA Cw6 in a patient had 35 fold higher risk of developing psoriasis. 
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PSORIASIS AND ADIPONECTIN 
Obesity is associated with decreased adiponectin, as proved in various 
studies psoriasis patients who are obese had decreased adiponectin level. 
Proinflammatory cytokines like Il-6 may suppress adiponectin. (31) 
 
PSORIASIS AND LEPTIN 
The functions of leptin one of the adipokine is to regulate the appetite, 
body weight by a feedback mechanism.other action includes skin 
regeneration, hair growth. Experiments have shown high levels of leptin acts 
as a proinflammatory mediator, resulting in Th1 cell response.Elevated levels 
of leptin is associated with intimal media thickness of great vessels and hence 
it is a marker of coronary artery disease and cardiovascular morbidity.Few 
reports have shown a positive correlation of leptin levels with the chronicity 
and duration of psoriasis, and thus it is involved in metabolic syndrome. (32) 
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PSORIASIS AND RESISTIN 
Proinflammatory cytokines like TNF alpha,IL-6, increases the levels of 
resistin which in turn increases IL-12, TNF alpha ,which is a mediator of 
endothelial dysfunction  and atherosclerosis.Similar to rhematoid arthritis, 
IBD, psoriasis disease also showed a positive correlation with resistin and its 
level decreased with systemic treatment of psoriasis. 
RBP4 is a marker of systemic insulin resistance and diabetes and found 
to be increased in psoriasis. omentine increases the sensitivity of insulin and 
helps in glucose uptake by adipocytes,its level remains unaltered in psoriasis 
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MAJOR ADIPOKINES IN PSORIASIS: 
 
Green arrow-up regulation: 
Red arrows -down regulation 
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ADIPOKINES IN PSORIASIS: 
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COMPARISON OF STUDIES : 
PREVALENCE OF METABOLIC SYNDROME AMONG 
PSORIASIS IN VARIOUS STUDIES 
Study No of 
pateints 
Prevalence 
of MS 
Results 
 
Prevalence of 
components of 
MS 
Correlation 
with 
severity of 
psoriasis 
Safiye 
kutlu et al 
250 30.8 Type 2 psoriasis 
was more  
common 
  
Gisondi 
et al 
338 30.1 MS was common 
in 1.35.2% of PA  
2.>40 years 
No significant 
difference in 
prevalence on 
low HDL, 
FPG, 
hypertension  
1.No 
correlation 
of MS 
 
2.Correlates  
withTGL 
 
Sommer 
et al 
  MS more in 
Moderate –severe 
psoriasis 
  
Takahashi 
et al 
    No 
correlation 
Nazhatun 
nisa et al 
150 28  Higher 
prevalence of 
TGL, FPG, 
HT 
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PREVALENCE OF DYSLIPIDEMIA AMONG PSORIASIS 
PATIENTS 
study No.of 
patient
s 
Dyslipidemi
a 
HDL TGL Chol LDL VLDL 
UK 44,164 4.3%  
(1.17 times)  
     
Iran   raised No 
chang
e 
raised  raised raised 
Zarijavidi 
et al 
 raised No 
chang
e 
raised  raised raised 
Turkey  84 raised  raised raised raised  
hyderaba
d 
79 raised No 
chang
e 
raised raised raised No 
chang
e 
Iran 
 
30 No change No 
chang
e 
No 
chang
e 
No 
chang
e 
No 
chang
e 
No 
chang
e 
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PREVALENCE OF CORONARY ARTERY DISEASE IN 
PSORIASIS: 
Azfar et al study with 32 patients based on coronary artery calcification 
showed a higher prevalence of CAD (59%) among severe psoriasis. 
A population based cohort study conducted in UK with 1,30,000 
psoriasis patients showed that young patients with severe psoriasis have a 
higher relative risk of 3.1 of developing CAD . 
Another study states that psoriasis patients have 1.21 times higher risk 
of developing CAD. (33) 
 
HYPERTENSION 
UK studied a prevalence of 6.3% psoriasis patients with hypertension. 
It is especially common among psoriasis patients with smoking, and 
alcoholics. Yet another study conducted in Israel states a prevalence of 27.5% 
of psoriasis patients with hypertension. 
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GUIDELINES FOR MONITORING PATIENTS FOR METABOLIC SYNDROME 
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TREATMENT OF PSORIASIS: 
Both topical and systemic therapies are available for the treatment of 
psoriasis Treatment of psoriasis should be individualized. 
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TREATMENT OF PSORIASIS WITH BSA < 20% 
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TREATMENT OF PSORIASIS WITH BSA > 20% 
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BIOLOGICAL THERAPIES IN PSORIASIS 
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Rotation of available therapy for moderate to severe psoriasis may avoid 
long term cumulative  systemic toxicity and use of drugs effectively and 
wisely. 
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NON ALCOHOLIC FATTY LIVER DISEASE 
Cryptogenic cirrhosis accounts for approximately 10-20% of causes for 
cirrhosis, of which nonalcoholic fatty liver disease (NAFLD) is the most 
common cause. 
It was Morgan in 1870 who initially described an association of fatty 
liver with obesity. In 1980, Ludwig et al observed characteristic features of 
alcoholic liver disease in liver biopsy specimens in patients who did not 
consume alcohol, neither used drugs that causes steatohepatitis. Hence he 
coined the term  nonalcoholic steatohepatitis (NASH ).   
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of condition 
ranging in severity from mild liver steatosis to very severe disease NASH 
which may progress to cirrhosis, liver failure, and hepatocellular cancer in 
patients without significant ethanol exposure. NAFLD is the most common 
liver disease in the world. (34) 
 
38 
 
 
SPECTRUM OF NAFLD 
 
 
DEFINITIONS AND TERMINOLOGY 
The criteria to diagnose NAFLD in a patient  necessitates exclusion of  
all other possible etiologies which can cause liver steatosis, such as 
significant alcohol consumption ,viral hepatitis, drug - induced injury ,Wilson 
’s disease, hemochromatosis  and α 1 - antitrypsin deficiency . 
Significant alcohol consumption for causing fatty liver is estimated as 30 
g/day in males and 20 g/day in females. (35) 
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NON ALCOHOLIC FATTY LIVER DISEASE(NAFLD):  
It is defined as fatty infiltration of more than 5-10% of liver by weight, 
or more than 5–10% of hepatocytes in biopsy specimens by light microscopy 
without any evidence of cell injury. 
 
NONALCOHOLIC STEATOHEPATITIS (NASH): 
It is the severe form of NAFLD wherein fatty infiltration of liver is 
associated with inflammation, ballooned hepatocytes, necroapoptosis , and 
fibrosis, usually beginning around the central vein. 
 
NON NASH FATTY LIVER (NNFL): 
It is synonymous to nonalcoholic fatty liver (NAFL), /simple steatosis, 
with minimal or no inflammation, and no fibrosis. 
 
PRIMARY NAFLD/NASH: 
If NAFLD or NASH is associated with central obesity, diabetes 
mellitus type 2, without any other specific etiology then it is primary 
NAFLD. 
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SECONDARY NAFLD or NASH: 
If NAFLD or NASH is due to drug inducedor toxin induced then it is 
secondary NAFLD. It is also called as toxin associated steatohepatitis(TASH)  
 
.EPIDEMIOLOGY 
NAFLD is usually detected in 4th or 5th decade of life .Population based 
studies have documented NAFLD in 10-24% of the population to as high as 
79% among obese individuals. It is more prevalent among Hispanics than 
other race. 
 
ETIOLOGY OF NAFLD 
Metabolic –congenital or acquired, and drugs 
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METABOLIC CAUSSES: 
CONGENITAL: 
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PATHOGENESIS OF NAFLD 
Day and James proposed “Two hit hypothesis” in 1998 
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CLINICAL FEATURES OF NAFLD 
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SYMPTOMS: 
Usually they are asymptomatic.NAFLD are detected incidentally, 
while screening for other disease. Occasionally patient may have right 
hypochondriac pain, discomfort,associated with fatigue and malaise.  
SIGNS: 
Hepatomegaly is present in nearly 75% of NAFLD. Other stigmata of liver 
cell failure like splenomegaly,spider angioma, ascites, may be in late stage of 
NAFLD when they progress cirrhosis. 
 
LABORATORY FEATURES OF NAFLD 
Elevation of liver enzymes are present in nearly 50% of patients with 
NAFLD. The liver enzymes will be elevated in nearly 80% of patients with 
advanced NAFLD induced cirrhosis.ALT will be elevated than AST . There 
will be a rise of 1.5 to 4 fold in liver enzyme level.it will never exceed 10 
fold. ANA may be positive in low titer in one fourth of the patients. Elevation 
of serum ferritin is a marker of advanced cirrhosis  (36) 
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IMAGING 
Ultrasonography of liver may reveal increased echogenicityof liver, it 
appears as bright liver. USG has a sensitivity of 100% in detecting a fatty 
liver. 
CT:In abdominal computer tomography–fatty liver appears less dense 
than spleen.  
MRI- fatty liver appears bright in T 1 weighted image 
For assessing the severity of fatty liver or grading, liver biopsy is 
needed and is confirmatory for the diagnosis and staging with certainty. 
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HISTOLOGY OF NNFL AND NASH: 
NAFLD is characterized by mixed macro ,micro ,medio vesicular 
steatosis ,but predominantly macrosteatosis,diffusely distributed ,but 
perivenular predominance is also noted. 
NASH is characterized by hepatitic steatosis as described above, which 
may correlate with BMI,plus  predominantly lobular inflammation with 
lymphocytes,macrophages,neutrophils  is the hallmark of NASH . 
Ballooning of hepatocytes ,presence of  “Mallory –Denk bodies” inside 
the inflamed hepatocytes, Perisinusoidal (zone 3), periportal, perivenular 
fibrosis may be noticed in advanced NASH . 
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DIAGNOSIS : 
Diagnosis of NAFLD requires both clinical, histologic parameters.A 
combination of history,physical examination,biochemical parameters 
,imaging modality is  needed to rule out other causes of steatohepatitis . 
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CLASSIFICATION  
LIVER BIOPSY: is a invasive, procedure with minimal complication. 
WORKING CLASSIFICATION OF 
NAFLD
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FIBROSIS STAGING OF NONALCOHOLIC 
STEATOHEPATITIS 
(NASH):
 
NON INVASIVE MARKERS OF FIBROSIS IN NAFLD 
Hematological parameters to estimate hepatic fibrosis includes total 
bilirubin, GGTP levels, apolipoprotein A-1, serum α2-macroglobulin, 
haptoglobin,serumdehydroepiandrosteronelevelsand serum hyaluronic acid 
levels. 
FIBROTEST: 
 Detects bridging fibrosis and cirrhosis a value >0.7 has a specificity of 
98% for advanced fibrosis. (35) 
Fibroscan (transient elastography): 
Quantifies liver stiffness and fibrosis. 
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NAFLD Fibrosis Score developed byAngulo et al,incorporates age, 
BMI, hyperglycemia, AST/ALT ratio, platelet count, and serum albumin 
level is yet another noninvasive method to quantify fibrosis. 
 
COURSE OF NAFLD: 
The course of NAFLD is favorable if there is no hepatic fibrosis, or 
cirrhosis. Few patients of  NAFLD can progress to liver failure, cirrhosis (3% 
) , hepatocellular carcinoma. 
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RISK FACTORS FOR ADVANCED NAFLD 
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TREATMENT OF NAFLD 
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METABOLIC SYNDROME: 
Metabolic syndrome comprises of cluster of metabolic risk factors 
which predisposes a person for cardiovascular disease. It was Reaven in 1988 
who observed this cluster of risk factors and he labeled these multiplex risk 
factors as syndrome X. Other terminologies used for this syndrome are 
insulin resistance syndrome, metabolic syndrome, and deadly quartet. 
 
COMPONENTS OF METABOLIC SYNDROME  
i) Raised blood pressure  
ii) Atherogenic dyslipidemia 
iii) Abdominal obesity 
iv) Insulin resistance glucose intolerance 
v) Prothrombotic state  
vi) Proinflammatory state  
Various criteria’s are put forth and consistently revised by 4 
organizations to identify individuals with this syndrome, for primary 
prevention of cardiovascular diseases, namely   
I. International Diabetes Federation (IDF) 
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II. National Cholesterol Education Program’s Adult Treatment Panel 
III (ATP III) 
III.WHO Clinical Criteria for Metabolic Syndrome 
IV. American Association of Clinical Endocrinologists (AACE) 
Clinical Criteria for diagnosis of the Insulin Resistance Syndrome 
V. European group for the study of insulin resistance (EGIR) 
 
CRITERIA FOR METABOLIC SYNDROME 
INTERNATIONAL DIABETES FEDERATION (IDF):  
Central obesity 
Based on waist circumference and adjusted according to the ethinicity of 
patient plus any two of the following 
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WAIST CIRCUMFERENCE BASED ON ETHINICITY 
Ethnic group Male(cm) Female(cm) 
South Asia ≥90 ≥80 
Chinese ≥90 ≥80 
Europe ≥94 ≥80 
Japanese ≥90 ≥80 
South and central 
America, African, 
eastern 
mediaterranean 
As per south 
asia 
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NATIONAL CHOLESTEROL EDUCATION PROGRAM’S ADULT 
TREATMENT PANEL III (ATP III) 
Any three or more of the following: 
Risk factors Defining level 
Central obesity  
Male 
Female 
Waist circumference(cm) 
>102 
>88 
Blood pressure ≥ 130/≥85mmHg 
Triglycerides ≥ 150mg/dL(1.7 mmol/L) 
HDL cholesterol 
Men 
female 
 
 
<40mg/dL(1.03mmol/L) 
<50mg/dL (1.29mmol/L) 
Fasting glucose ≥110mg/dL(6.1 mmol/L) 
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WHO CRITERIA FOR METABOLIC SYNDROME 
Impaired glucose regulation or diabetes mellitus 
Presence of insulin resistance (hyperinsulinemic glycemic condition) 
Plus two ormore of the following: 
Risk factors Defining level 
Central obesity  
Male 
Female 
waist –hip ratio 
>0.90 
>0.85 or  
BMI>30 kg/m2 
Blood pressure ≥140/90mmHg 
Triglycerides ≥ 150mg/dL(1.7 mmol/L) 
HDL cholesterol 
Men 
female 
 
35mg/dL (0.9mmol/L): 
39mg/dL (<1.0mmol/L) 
1) Microalbuminuria urine albumin excretion rate ≥20g/min 
albumin : creatinine ratio >30mg/g 
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PATHOGENESIS OF METABOLIC SYNDROME: 
 
Obesity and insulin resistance are responsible for the components of 
metabolic syndrome and hence risk for CVD, and type 2 diabetes. 
 
EFFECT OF OBESITY AND INSULIN RESISTANCE: 
Obesity leads to excess of adipose tissue and when insulin resistance 
occurs there is impaired antilipolytic activity of insulin. This result in 
increased lipolysis and increase in free fatty acid, which gets deposited in 
liver and muscle .other effects of insulin resistance include decreased insulin 
mediated glucose uptake in liver ,muscle, increased triglyceride and 
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lipoprotein formation like VLDL,LDL in liver .increased glucose and FFA in 
circulation results hyperinsulinemic state .  
Increased reabsorption of sodium and increased sympathetic nervous 
system activity due to hyperinsulinemiaresults in hypertension in metabolic 
syndrome. 
EFFECTS OF CYTOKINES 
IL-6 ,TNF alpha are produced from the excess adipose tissue .this 
enhances the insulin resistance  ,increases conversion of  triglyceride to FFA, 
hepatic production of glucose, CRP, fibrinogen, adipocyte production of  PAI 
resulting in a proinflammatory and prothrombotic state respectively . 
Reduced levels of anti-inflammatory, insulin sensitizing cytokine 
adiponectin also predisposes to metabolic syndrome. 
Role of adiponectin in metabolic syndrome: Adiponectin is an 
antiinflammatory cytokine produced exclusively by adipose tissue. It 
increases the insulin sensitivity, reduces the rate of glucose production by 
liver.in muscle it enhances the glucose uptake, fatty acid oxidation. Reduced 
adiponectin may contribute to the development of metabolic syndrome and it 
correlates with the development of metabolic syndrome. 
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RISK FACTORS FOR METABOLIC SYNDROME 
1) Overweight/obesity 
2) Sedentarylifestyle 
3) Diabetes mellitus 
4) Coronary artery disease 
5) Lipodystrophy 
6) Aging 
 
CLINICAL FEATURES OF METABOLIC SYNDROME 
On examination signs which should alert a clinician for features of 
metabolic syndrome includes elevated blood pressure, increased waist 
circumference lipodystrophy, acanthosis nigricans and features of other 
associated diseases due to metabolic syndrome. 
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ASSOCIATED DISEASE 
Cardiovascular disease, type 2 diabetes, nonalcoholic fatty liver 
disease , hyperuricemia, polycystic ovary syndrome, obstructive sleep apnea 
syndrome. 
DIAGNOSIS 
An individual must satisfy the criteria for metabolic syndrome based 
on examination and laboratory parameters. 
Biomarkers for supporting the diagnosis and research in metabolic syndrome: 
 
BIOMARKERS FOR SUPPORTING DIAGNOSIS AND 
RESEARCH IN METABOLIC SYNDROME 
Measuring abnormal body fat 
distribution 
Adipose tissue marker- leptin, 
adiponectin 
Liver fat distribution-MRS 
General body fat distribution-DEXA 
Abdominal fat distribution-CT/MRI 
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Atherogenic dyslipidaemia Apo B, (non HDL c),,small LDL 
particles 
Glycemic status OGTT 
Insulin resistance Fasting insulin /proinsulin levels, 
HOMA-IR 
Free fatty acid level (fasting and post 
prandial) 
Insulin resistance by Bergman 
minimal model 
M value from clamp 
Uric acid 
Prothrombotic state Fibrinolytic factors-PAI 
Clotting factors-fibrinogen 
Proinflammatory state High sensitivity C-reactive protein 
IL-6,TNF alpha, 
Adiponectin 
Vascular dyregulation Microalbuminuria 
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Other tests which supports the diagnosis includes liver function test, 
uric acid level, sleep study if patient has obstructive sleep apnea. 
 
PREVENTION OF CVD 
LIFESTYLE MODIFICATION AND WEIGHT REDUCTION 
Physical activity of  60–90 min of daily activity is 
recommended.indifficult situations at least 30 min of moderate-intensity daily 
activity is recommended .this has proved to reduce the blood pressure, serum 
cholesterol, triglycerides levels, PAI, CRP levels, insulin resistance , 
increases HDL level. 
 
DIET: 
High-quality diet with high quantity of fruits, vegetables, whole grains, 
lean poultry, and fish. Diets restrictedin carbohydrates, saturated fats (<7% of 
calories), trans-fats (as few as possible), and cholesterol (<200 mg daily)are 
advised. 
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OBESITY 
Appetite suppressants -phentermine, sibutramine can be used on short 
term , fat absorption inhibitor-orlistat are found to reduce the incidence of 
diabetes. Bariatric surgery ,gastric bypass surgery can be considered in 
individuals with  BMI >35-40kg/m2. 
 
DYSLIPIDEMIA 
LDL CHOLESTEROL  
Targeted LDL cholesterol goal is <130 mg/dL  in patients with history 
of CVD the goal is <100 mg/dL .in uncontrolled individuals drugs like 
statins, cholesterol absorption inhibitor ezetimibe can be used. Fibrates 
especially fenofibrate is used when both LDL cholesterol and triglcerides are 
elevated. Nicotinic acid has modest benefit in lowering LDL cholesterol. Bile 
acid sequestrants cholestyramine and colestipol can be when LDL cholesterol 
alone is elevated as it may increase the triglycerides.  
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TRIGLYCERIDES: 
 Fibrates are the drug of choice for lowering the triglyceride level. 
other drugs which can lower triglycerides include statins, nicotinic acid, and 
high doses of omega-3 fatty acids. 
 
HDL CHOLESTEROL: 
Nnicotinic acid is the only drug which can raise the HDL cholesterol 
level. 
Drugs that reduces insulin sensitivity includes metformin and 
thiazolidinediones. 
 
HYPERTENSION 
Antihypertensive drugs as per hypertension guidelines should be 
prescribed. ACE inhibitors or ARB‘s are preferred for hypertensive without 
diabetes. Low dose aspirin as antithrombotic are other drugs which are 
proved to reduce the CVD and can be used as primary and secondary 
prevention. 
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NEWER GROUP OF DRUGS IN CLINCSL TRIAL: 
PPAR agonists interacting with both alpha and gamma receptors, 
incretin mimics, protein tyrosine phosphatase IB inhibitors, endocannabinoid 
receptor inhibitor, dipeptidyl peptidase IV inhibitors are under trial. 
Monitoring of  individuals with metabolic syndrome: 
 
 
 
 
 
 
  
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
SELECTION OF PATIENTS: 
All subjects were explained about the psoriasis and its comorbidities. 
All patients were informed about the proceedings of the study and the 
advantage of participating in the study in their own language. 
Consents were obtained from all the subjects before participating in the study 
 
STUDY DESIGN:   
Cross sectional study 
 
STUDY CENTRE: 
Institute of Dermatology Venereology and Leprosy,  
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai 
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DURATION OF THE STUDY 
6 months April 2014 toSeptember 2014 
 
INCLUSION CRITERIA 
Patients diagnosed with psoriasis, aged>20 years, who are willing to         
participate in the study were included. 
 
EXCLUSION CRITERIA 
i) Psoriasis patients on hepatotoxic drugs, such as methotrexate, 
corticosteroids, psoralens, acitretin, oral contraceptive pills, tamoxifen, 
antituberculous drugs.  
 ii) Patients with significant alcohol use  Consumption of more than 20 
to 40 g of alcohol.(2 standard drinks in female and 3 standard drinks in male 
per day). 
iii) Patients who are not willing to participate in our study. 
iv) H/S/O hemochromatosis, Wilson’s disease, 
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SAMPLE SIZE 
A total of 165 patients were included in the study. 
.  
DATA COLLECTION METHOD 
All patients included in our study are subjected to a thorough  
1. Clinical history,  
2. General examination, 
3. Clinical examination,  
4. Dermatologicalexamination, 
5. Blood investigation, 
6.Ultrasonography by Radiologist  
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METHODOLOGY: 
HISTORY: 
A detailed history on psoriasis and H/S/O any comorbid illness were 
collected.  
The particulars include, 
Age 
Sex 
Duration of psoriasis 
Site of involvement  
H/O arthritis 
H/O Diabetes mellitus, hypertension, abdomen symptoms like pain, 
discomfort, jaundice. 
Treatment history 
H/O Alcohol consumption if present- type, quantity, and duration of alcohol 
intake. 
GENERAL EXAMINATION 
For all subjects the following parameters were assessed. 
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1. BMI based on weight and height using the formula weight/height in meters 
2 
2. Waist circumference was measured by placing a measuring tape around the 
abdomen at the level of the iliac crest, firmly. 
3. Blood pressure was measured in sitting posture on the right arm. 
4. Other general examination was done in all subjects. 
 
SYSTEMIC EXAMINATION 
The following systems were examined  
Abdomen: patients were examine for the presence of organomegaly 
especially hepatomegaly. 
Cardiovascular system 
Central nervous system  
Respiratory system. 
 
DERMATOLOGICAL EXAMINATION 
All confirmed cases of psoriasis either clinically or based on 
histopathology were examined and data collected on 
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1. Type of psoriasis  
2. Site of involvement 
3. Presence of psoriatic arthritis 
4. PASI calculated to assess the severity 
 
PROCEDURE / INVESTIGATION DETAILS: 
Patients will be subjected to blood investigations like 
 Liver function tests including   
o AST, ALT,  
 Fasting blood glucose 
 Fasting lipid profile which includes 
o Serum triglycerides 
o Serum cholesterol 
o Serum High density lipoprotein. 
 
Based on the above parameters, the presence of metabolic syndrome is 
identified using , INTERNATIONAL DIABETES FEDERATION(IDF) 
 
All patients are subjected to ultra sonogram of the abdomen in empty 
stomach 
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Patients who are found to have nonalcoholic fatty liver by USG, are subjected 
to anti HCV,  
HBs Ag  
 
ANALYSIS PLAN 
Statistical analysis was done using SPSS version 17.0 
 
SPONSORSHIP : 
 NO 
 
CONFLICT OF INTEREST : 
None 
 
 
 
 
  
 
 
 
OBSERVATION 
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OBSERVATION AND RESULTS  
A total of 165 patients participated in our study. Of them 98 (59.3%) 
are males and 67(40.6%) are females .They are distributed in the age group 
from 20 years to 72 years .All the  subjects are categorized based on the 
severity  by PASI  score and analyzed. Our patients had PASI score ranging 
from as low as 5 to 60.Majority of the subjects are  males in the age group 30 
to 50. Majority of them belonged to PASI score of 11-30 group. 
FIGURE 1 
DISTRIBUTION OF PATIENTS ACCORDING TO PASI 
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FIGURE 2 
SEX WISE DISTRIBUTION OF PSORIASIS PATIENTS 
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OBESITY: 
TABLE 1  
PSORIASIS PATIENTS AND BODY MASS INDEX 
PASI NO.OF PATIENTS  
TOTAL <22.9 23-27.49 >27.5 
0-10 25(41%) 21(32.3%) 16(41%) 62(37.6%) 
11-30 24(39.3%) 26(40%) 20(51.3%) 70(42.4%) 
31-50 8(13.1%) 7(10.8%) 2(5.1%) 17(10.3%) 
51-72 4(6.6%) 11(16.9%) 1(2.6%) 16(9.7%) 
TOTAL 61(37%) 65(39%) 39(24%) 16(95) 
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FIGURE 3 
 
39(24%) of our patients are obese, and patients belonging to PASI 
score 11-30  years had increased BMI 
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Waist circumference based on IDF criteria ,39.4% of patients are found 
to have central obesity. 
 
FIGURE 4  
DISTRIBUTION BASED ON WAIST CIRCUMFERENCE 
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HYPERTENSION 
43(26.1%) of 165 patients had hypertension, of which 12 out of 165 
patients are newly detected to have hypertension , and the remaining  are 
already on treatment. Of these only 6 are < 40 years , and the rest are >40 
years. 
FIGURE 5  
HYPERTENSION IN OUR STUDY 
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FASTING BLOOD GLUCOSE  
55(33.3%) out of 165 had hyperglycemia. Of them 8 are newly detected. 
Remaining patients are on medications. 
 
FIGURE 6   
HYPERGLYCEMIC STATUS 
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DYSLIPIDEMIA: 
Fasting lipid profile is deranged in large number of patients 
significantly. Triglycerides , cholesterol are elevated in 60(36%)  and 
35(21%)patients. 
Whereas reduced HDL is found in 65(39%) patients. 
 
FIGURE 7  
DYSLIPIDEMIA IN PSORIASIS 
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LIPOPROTEIN LEVELS IN OUR STUDY 
FIGURE 8 
 
85 
 
 
FIGURE 9  
TRIGLYCERIDE LEVELS IN OUR PATIENTS 
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FIGURE 10  
CHOLESTEROL LEVELS IN OUR PATIENTS 
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SYSTOLIC AND DIASTOLIC BLOOD PRESSURE  
IN OUR STUDY 
FIGURE 11 
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PSORIASIS NONALCOHOLIC FATTY LIVER: 
On Ultrasonography around 75(45.5%) are found to have NAFLD. The 
prevalence of NAFLD is estimated as 45.5%. 
Of these patients 16 had metabolic syndrome   
They are present predominately in 11-30 PASI score. 
They were distributed equally in all age groups, and in duration of 
illness. 
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FIGURE 12 
PREVALENCE OF NON ALCOHOLIC FATTY LIVER 
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FIGURE 13 
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AST  LEVEL IN OUR STUDY 
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ALT LEVEL IN OUR STUDY 
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PSORIASIS AND METABOLIC SYNDROME 
 In our study 27 patients are found to have metabolic syndrome. Most 
of them are in the age group >40 and in PASI group 11-30  and  
predominately males. 
17 of them are in PASI score of 11-30 
16 patients had the duration of illness >3years 
 
AGE AND SEX DISTRIBUTION OF METABOLIC 
SYNDROME 
 AGE SEX 
<40 >40 MALE FEMALE 
NO.OF 
PATIENTS 
MS 
7(4%) 20(12%) 16(9%) 11(6%) 
TOTAL 27(16%) 27(16%) 
 
 
  
 
 
 
DISCUSSION 
  
95 
 
 
DISCUSSION 
Psoriasis is a systemic illness involving almost all system in the body. 
It is a chronic inflammatory state , mediated by T helper cell and its 
cytokines. The role of adipokines in psoriasis is of recent interest. Various 
experiments have proved its role in psoriasis.  
Of the comorbidities, metabolic syndrome is  more prevalent among 
psoriasis patients and is considered as a high risk for developing coronary 
artery disease. NAFLD is now regarded as the hepatic manifestation of  
metabolic syndrome. Hence our objective of the study is to find the 
magnitude of NAFLD and metabolic syndrome among psoriasis patients.  
The prevalence of  NAFLD among normal population is estimated as 
20-30% across various countries. The prevalence of NAFLD in India is 
reported as 9-19%  in adult population. 
PSORIASIS AND NAFLD: 
In our study NAFLD is found in 75(45.5%) of the patients. Similar to 
previous other studies, the prevalence of  NAFLD is increased in our study. 
Van der voort et al. study have documented 46.2%  prevalence of NAFLD in 
psoriasis . Miele et al has reported a prevalence of 59.2%.among psoriasis 
patients. Gisondi et al, have found a prevalence of  NAFLD  in 47% of 
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patients with psoriasis. Madanagobalane et al showed  a prevalence of 17.4% 
in south Indian population. 
 In our study NAFLD is seen distributed equally in all age group 
,both the sex, and irrespective of the duration of illness. This is similar to the 
study by Gisondi et al in which the prevalence of NAFLD did not vary with 
age, gender, body mass index, psoriasis duration. 
Compared to other studies  like Gisondi et al, who had observed more 
prevalence of NAFLD in chronic plaque psoriasis and Madanagobalane et al 
study in which they found an association of NAFLD with  psoriatic arthritis, 
we did not find any association with any specific type of psoriasis.  
Our study showed predominant distribution of psoriasis patients with 
NAFLD in PASI group 11-30 years as compared with other studies like 
Gisondi et al study which also  showed a correlation of NAFLD with the 
severity of psoriasis and  higher PASI score.  
Our psoriasis pateints with NAFLD are found to be associated with  
obesity ,dyslipidemia, and metabolic syndrome in our study. Other studies 
have reported similar observation. This is probably due to a similar 
pathogenesis which is common to both psoriasis and NAFLD. 
Adipocytokines have a role in psoriasis as well as NAFLD. 
Hypoadiponectinemia is associated with psoriasis. Takahashi et al have found 
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a correlation of  decreased adiponectin levels with  psoriasis disease severity. 
Shibata et al have shown that serum adiponectin  levels increases after 
psoriatic therapy. 
PSORIASIS AND METABOLIC SYNDROME 
The prevalence of metabolic syndrome in our study is 27(16%).All other 
components are also increased in our study. 
PREVALENCE OF VARIOUS COMPONENTS OF METABOLIC 
SYNDROME IN OUR STUDY. 
TOTAL NO.OF PATIENTS-165 
COMPONENTS OF MS NO,OF PATIENTS  
OBESITY 39(24%) 
HT 43(26.1%) 
FPS 55(33.3%) 
TGL 60(36%) 
HDL 65(39%) 
CHOL 35(21%) 
FATTY LIVER 75(45.5%) 
MS 27(16%) 
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In our study metabolic syndrome is present predominately in males, 
above 40 years. The components of metabolic syndrome like hypertension, 
central obesity, diabetes are also seen predominately in above 40years. A 
study by Gisondi et al , and Madanagobalane et al also showed  a similar 
result. 
Madanagobalane et al study showed a prevalence of 44.1% of 
metabolic syndrome .Other studies like Safiye kutlu et al study ,Gisondi et al 
quote a prevalence of 30.8 % and 30.1% respectively. 
  Our psoriatic patients are found to have higher prevalence of central 
obesity 39(24%) and dyslipidemia which includes low HDL 65(39%), 
triglycerides 60(36%) and cholesterol 35(21%). This is similar to other study 
like Madanagobalane et al where they have observed  an increased prevalence  
of  triglyceridemia (33.9% ) abdominal obesity (34.7% ), but there was no 
difference in the high density lipoprotein (HDL) levels . Gisondi et al have 
observed no significant difference in prevalence on low HDL, Whereas 
Nazhatun nisa et al have observed a higher prevalence of   low TGL. Other 
studies conducted in Iran ,UK, Hyderabad have found significant 
dyslipidemia in psoriasis. 
Our study found a correlation of increased prevalence of metabolic 
syndrome in those with longer duration of illness, and in those with 
hyperglycemia.  We did not find any correlation of metabolic syndrome with 
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the severity of psoriasis, hypertension , diabetes. Study by Madanagobalane 
et al   showed no correlation with severity of psoriasis, duration , 
hypertension and HDL. Study by Neimann AL showed a higher prevalence of 
diabetes in severe psoriasis. 
Almost all the patients with metabolic syndrome had NAFLD in our 
study, similar to other studies 
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CONCLUSION 
 Psoriasis is significantly associated with NAFLD and metabolic 
syndrome. 
Increased prevalence of NAFLD indicates that psoriasis is independently 
associated with NAFLD.   
Physicians should consider the possibility of chronic hepatic 
involvement in psoriasis before administering any hepatotoxic drug. 
Psoriasis is no longer just skin deep, it is a chronic inflammatory multi 
system disease.  
Patients should be screened for nonalcoholic fatty liver before 
administering any hepatotoxic drug and treatment planning should be done 
taking into consideration of various cardio metabolic comorbidities. 
 Psoriatic patients with metabolic syndrome should be educated about 
lifestyle modifications and they should be administered cardio protective 
drugs along with the psoriasis medications.  
Psoriatic patients should be regularly screened for diabetes, 
atherosclerosis, and liver disease. 
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ANNEXURES 
ABBREVIATIONS 
FFA   : Free fatty acid 
SAPHO  :  Synovitis, acne, Pustulosis, hyperostosis,  
and osteitis 
PsA                        : Psoriatic arthritis 
ALT    : Alanine aminotransferase 
ALP    : Aspartate aminotransferase. 
ANA   : Anti-nuclear antibody                      
USG   : Ultrasonogram 
CT   : Computed tomography 
MRI   : Magnetic Resonance Imaging 
TGL   : Triglycerides 
LDL   : Low density lipoprotein 
CHOL  : Cholesterol 
HDL   : High density lipoprotein  
VLDL  : Very low density lipoprotein 
Th1   : T helper cell 1 
APC   : Antigen presenting cell 
TNF alpha  : Tumor necrosis factor alpha 
IL   : Interleukin  
VEGF  : Vascular endothelial growth factor 
CAD   : Coronary artery disease 
CVD   : Cardiovascular disease 
BMI   : Body mass index 
PASI   : Psoriasis Area Severity Index 
BSA   : Body surface area 
VAS   : Visual analogue scale 
NAFLD  : Nonalcoholic fatty liver 
COPD  : Chronic obstructive pulmonary disease 
DM   : Diabetes mellitus 
MS   : Metabolic syndrome 
HT                          : Hypertension 
NCEP –ATP III      : National cholesterol Education Programmes  
    Adult Panel III 
PROFORMA 
Prevalence of nonalcoholic fatty liver disease and metabolic syndrome in 
psoriasis in a tertiary health center 
Name : Patient ID No: 
Age/Sex :  
Duration of illness:     Contact No: 
 
TYPE OF PSORIASIS 
☐
 Chronic plaque psoriasis   ☐ Psoriasis vulgaris 
☐
  Psoriatic arthritis    ☐ Palmoplantar psoriasis   
☐
 Unstable psoriasis                             ☐ Erythrodermic psoriasis 
☐
 Pustular psoriasis     
 
PASI SCORE 
☐
 0-10                     ☐ 10-30☐ 30-50 ☐ 50-72 
 
EXAMINATION   :         BP: sitting                     mmHg;     
WEIGHT:     HEIGHT:     BMI: 
Waist circumference 
 
INVESTIGATIONS 
Fasting blood glucose:  mg/dl 
 
Fasting lipid profile: 
Serum cholesterol       mg/dl 
Serum triglycerides      mg/dl 
Serum HDL                                                               mg/dl 
Liver function test: 
Serum bilirubin                                                         mg/dl  
Aspartate aminotransferase(AST)                      IU/L     
Alanine aminotransferase (ALT)                               IU/L         
AST/ALT                                                            
CRP                                                     
Urine microalbumin:                                                mg/dl 
Ultrasonogram of abdomen: 
 
 
Anti HCV antibody -                                 HBs Ag- 
 

  
 
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
 
 
 
   
INFORMATION SHEET 
 
We are conducting a study on “Prevalence of nonalcoholic fatty liver 
disease and metabolic syndrome in psoriasis in a tertiary health center”  
among patients attending Rajiv Gandhi Government General Hospital, Chennai 
and for that your specimen may be valuable to us. 
The purpose of this study is to assess prevalence of non alcoholic fatty 
liver disease and metabolic syndrome in psoriasis. We are selecting certain 
cases and if you are found eligible, blood pressure, BMI, waist circumference 
will be checked. 5ml blood will be collected in fasting state and 2ml of urine 
will be collected. You will also undergo ultrasound abdomen and if found to 
have liver enlargement fibro scan will be taken. These tests and special studies 
do not affect your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
 
 
Signature of Investigator Signature of Participant 
 
 
Date : 
Place : 

PATIENT CONSENT FORM 
 
Study Title : Prevalence of nonalcoholic fatty liver disease and 
metabolic syndrome in psoriasis in a tertiary health  
center 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Name :  
Age/Sex :  
Identification Number :  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to me in my 
own language ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. 
I agree not to restrict the use of any data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform 
the study staff if I suffer from any deterioration in my health or wellbeing or any 
unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and diagnostic tests 
including hematological and biochemical tests. ❏ 
 
 
Signature/thumb impression 
Patient’s Name and Address:
Signature of Investigator 
Study Investigator’s Name: 
Dr. S.ABARNA DEVI 
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2 
KEY TO MASTER CHART 
 
S.NO  - Serial number 
M          - Male 
F           -  Female 
BMI     - Body mass index 
WC   - Waist circumference in cm 
BP   - Blood pressure 
FBS     - Fasting blood sugar in mg/dl 
FLP     - Fasting lipid profile 
TGL     - Serum triglycerides in mg/dl 
HDL     - Serum high density lipoprotein in mg/dl 
CHOL   - Serum cholesterol in mg/dl 
AST        - Aspartate aminotransferase. 
ALT        -    Alanine aminotransferase 
USG         - Ultrasonogram of abdomen 
FL           - Fatty liver 
N            -  Normal 
PASI       -  Psoriasis area severity index 
DT           -  Duration of illness 
PV         - Psoriasis vulgaris 
CPP        - Chronic plaque psoriasis 
PA           - Psoriatic arthritis 
PPP      - Palmoplantar psoriasis 
PUP     - Pustular psoriasis 
UP       -  Unstable psoriasis 
SP        - Scalp psoriasis 
NP        -  Nail psoriasis 
PE               -  Erythrodermic Psoriasis  
GP              - Guttate psoriasis 
DT      - Duration of illness 
Y          - Year 
 
 
 
 
 
 
